23 related articles for article (PubMed ID: 16978223)
1. Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes.
Zhou JD; Zhang TJ; Xu ZJ; Deng ZQ; Gu Y; Ma JC; Wen XM; Leng JY; Lin J; Chen SN; Qian J
Cell Death Dis; 2020 Nov; 11(11):997. PubMed ID: 33219204
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of prognosis-related DLX5 methylation as an epigenetic driver in myeloid neoplasms.
Zhang TJ; Xu ZJ; Gu Y; Wen XM; Ma JC; Zhang W; Deng ZQ; Leng JY; Qian J; Lin J; Zhou JD
Clin Transl Med; 2020 Jun; 10(2):e29. PubMed ID: 32508046
[TBL] [Abstract][Full Text] [Related]
3. Realgar (α-As
Zhang M; Zhang JY; Sun MQ; Lu P; Liu JX
Chin J Integr Med; 2022 Mar; 28(3):281-288. PubMed ID: 32418175
[TBL] [Abstract][Full Text] [Related]
4. High methylation of the 4-aminobutyrate aminotransferase gene predicts a poor prognosis in patients with myelodysplastic syndrome.
Zhao G; Li N; Li S; Wu W; Wang X; Gu J
Int J Oncol; 2019 Feb; 54(2):491-504. PubMed ID: 30535457
[TBL] [Abstract][Full Text] [Related]
5. Karyotype and DNA-Methylation Responses in Myelodysplastic Syndromes following Treatment with Traditional Chinese Formula Containing Arsenic.
Shuzhen S; Rou M; Xiaomei H; Xiao-Hong Y; Yong-Gang X; Hongzhi W; Xiu-Peng Y
Evid Based Complement Alternat Med; 2012; 2012():969476. PubMed ID: 23118798
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation of SHP-1 promoter in patient with high-risk myelodysplastic syndrome and it predicts poor prognosis.
Zhang Y; Zhao D; Zhao H; Wu X; Zhao W; Wang Y; Xia B; Da W
Med Oncol; 2012 Dec; 29(4):2359-63. PubMed ID: 22258937
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia.
Griffiths EA; Gore SD; Hooker CM; Mohammad HP; McDevitt MA; Smith BD; Karp JE; Herman JG; Carraway HE
Epigenetics; 2010 Oct; 5(7):590-600. PubMed ID: 20671427
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.
Shen L; Kantarjian H; Guo Y; Lin E; Shan J; Huang X; Berry D; Ahmed S; Zhu W; Pierce S; Kondo Y; Oki Y; Jelinek J; Saba H; Estey E; Issa JP
J Clin Oncol; 2010 Feb; 28(4):605-13. PubMed ID: 20038729
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.
Vannucchi AM; Guglielmelli P; Rambaldi A; Bogani C; Barbui T
J Cell Mol Med; 2009 Aug; 13(8A):1437-50. PubMed ID: 19522842
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome.
Brakensiek K; Länger F; Schlegelberger B; Kreipe H; Lehmann U
Br J Haematol; 2005 Jul; 130(2):209-17. PubMed ID: 16029449
[TBL] [Abstract][Full Text] [Related]
11. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
Wang H; Wang XQ; Xu XP; Lin GW
Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of SOCS1 methylation in myelodysplastic syndrome.
Wu SJ; Yao M; Chou WC; Tang JL; Chen CY; Ko BS; Huang SY; Tsay W; Chen YC; Shen MC; Wang CH; Yeh YC; Tien HF
Br J Haematol; 2006 Nov; 135(3):317-23. PubMed ID: 16978223
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of aberrant SOCS-1 gene promoter methylation in myelodysplastic syndromes patients.
Chaubey R; Sazawal S; Mahapatra M; Chhikara S; Saxena R
Int J Lab Hematol; 2015 Apr; 37(2):265-71. PubMed ID: 25123164
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic Value of Multigene Methylation in Patients with Myelodysplastic Syndrome].
Deng CY; Chen S; Jiang M; Nilupar T; Wang H; Hao JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1118-1122. PubMed ID: 28823279
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Value of p15, DAPK, SOCS1 and FHIT Genes Combined Detection in the Early Diagnosis and Prognosis Evaluation of Myelodysplastic Syndrome].
Deng CY; Chen S; Jiang M; Chen R; Nilupar T; Wang H; Hao JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1751-1755. PubMed ID: 29262910
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
